These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23106932)

  • 61. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings.
    Meijer JH; Dekker N; Koeter MW; Quee PJ; van Beveren NJ; Meijer CJ;
    Psychol Med; 2012 Apr; 42(4):705-16. PubMed ID: 21899795
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Modeling metabolic syndrome and its association with cognition: the Northern Manhattan study.
    Levin BE; Llabre MM; Dong C; Elkind MS; Stern Y; Rundek T; Sacco RL; Wright CB
    J Int Neuropsychol Soc; 2014 Nov; 20(10):951-60. PubMed ID: 25382144
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mental state attribution, neurocognitive functioning, and psychopathology: what predicts poor social competence in schizophrenia best?
    Brüne M; Abdel-Hamid M; Lehmkämper C; Sonntag C
    Schizophr Res; 2007 May; 92(1-3):151-9. PubMed ID: 17346931
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Linkage of cognitive impairments with metabolic disorders in schizophrenia.
    Nasrallah HA
    Am J Psychiatry; 2010 Oct; 167(10):1155-7. PubMed ID: 20889659
    [No Abstract]   [Full Text] [Related]  

  • 67. Cognitive deficits and its relation with psychopathology and global functioning in first episode schizophrenia.
    Hegde S; Thirthalli J; Rao SL; Raguram A; Philip M; Gangadhar BN
    Asian J Psychiatr; 2013 Dec; 6(6):537-43. PubMed ID: 24309868
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns.
    González-Blanch C; Alvarez-Jiménez M; Rodríguez-Sánchez JM; Pérez-Iglesias R; Vázquez-Barquero JL; Crespo-Facorro B
    Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):364-71. PubMed ID: 16788772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cognitive deficits and social functioning in schizophrenia: a clinical perspective.
    van Beilen M; Kiers HA; Bou A; van Zomeren EH; Withaar FK; Arends J; van den Bosch RJ
    Clin Neuropsychol; 2003 Nov; 17(4):507-14. PubMed ID: 15168915
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia.
    Andersen R; Fagerlund B; Rasmussen H; Ebdrup BH; Aggernaes B; Gade A; Oranje B; Glenthoj B
    Psychiatry Res; 2011 May; 187(1-2):49-54. PubMed ID: 21075453
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Associations between components of metabolic syndrome and cognition in patients with schizophrenia.
    Goughari AS; Mazhari S; Pourrahimi AM; Sadeghi MM; Nakhaee N
    J Psychiatr Pract; 2015 May; 21(3):190-7. PubMed ID: 25955261
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Social skills and behavioral problems in schizophrenia: the role of mental state attribution, neurocognition and clinical symptomatology.
    Brüne M; Schaub D; Juckel G; Langdon R
    Psychiatry Res; 2011 Nov; 190(1):9-17. PubMed ID: 20417974
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is quality of life associated with cognitive impairment in schizophrenia?
    Alptekin K; Akvardar Y; Kivircik Akdede BB; Dumlu K; Işik D; Pirinçci F; Yahssin S; Kitiş A
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):239-44. PubMed ID: 15694230
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
    Huguelet P; Nicastro R; Zanello A
    Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The association between self-disorders and neurocognitive dysfunction in schizophrenia.
    Haug E; Øie M; Melle I; Andreassen OA; Raballo A; Bratlien U; Lien L; Møller P
    Schizophr Res; 2012 Mar; 135(1-3):79-83. PubMed ID: 22137461
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.
    Chang WC; Ming Hui CL; Yan Wong GH; Wa Chan SK; Ming Lee EH; Hai Chen EY
    J Clin Psychiatry; 2013 Nov; 74(11):e1046-53. PubMed ID: 24330905
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia.
    Üçok A; Direk N; Koyuncu A; Keskin-Ergen Y; Yüksel Ç; Güler J; Karadayı G; Akturan E; Devrim-Üçok M
    Schizophr Res; 2013 Dec; 151(1-3):265-9. PubMed ID: 24262680
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables.
    Yu M; Tang X; Wang X; Zhang X; Zhang X; Sha W; Yao S; Shu N; Zhang X; Zhang Z
    PLoS One; 2015; 10(9):e0138357. PubMed ID: 26381645
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neurocognitive functioning in drug-naive patients with first episode of psychosis before and after treatment.
    Zaytseva Y; Gurovich I; Sarkisyan G; Sarkisyan V
    Psychiatr Danub; 2011 Sep; 23 Suppl 1():S155-7. PubMed ID: 21894125
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia.
    Fan X; Liu EY; Freudenreich O; Park JH; Liu D; Wang J; Yi Z; Goff D; Henderson DC
    Schizophr Res; 2010 May; 118(1-3):211-7. PubMed ID: 20189773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.